Cover Image

cMET: a prognostic marker in papillary renal cell carcinoma?

The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PANZAR consor...

Full description

Saved in:
Bibliographic Details
Main Authors: Erlmeier, Franziska (Author) , Bruecher, Benedict (Author) , Stöhr, Christine (Author) , Herrmann, Edwin (Author) , Polifka, Iris (Author) , Agaimy, Abbas (Author) , Trojan, Lutz (Author) , Ströbel, Philipp (Author) , Becker, Frank (Author) , Wülfing, Christian (Author) , Barth, Peter (Author) , Stöckle, Michael (Author) , Staehler, Michael (Author) , Stief, Christian Georg (Author) , Haferkamp, Axel (Author) , Hohenfellner, Markus (Author) , Macher-Göppinger, Stephan (Author) , Wullich, Bernd (Author) , Noldus, Joachim (Author) , Brenner, Walburgis (Author) , Roos, Frederik C. (Author) , Walter, Bernhard (Author) , Otto, Wolfgang (Author) , Burger, Maximilian (Author) , Schrader, Andres Jan (Author) , Hartmann, Arndt (Author) , Mondorf, Yvonne (Author) , Ivanyi, Philipp (Author) , Mikuteit, Marie (Author) , Steffens, Sandra (Author)
Format: Article (Journal)
Language:English
Published: 6 January 2022
In: Human pathology
Year: 2022, Volume: 121, Pages: 1-10
ISSN:1532-8392
DOI:10.1016/j.humpath.2021.12.007
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.humpath.2021.12.007
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S004681772100215X
Get full text
Author Notes:Franziska Erlmeier MD, Benedict Bruecher MD, Christine Stöhr PhD, Edwin Herrmann Prof, Iris Polifka MD, Abbas Agaimy Prof, Lutz Trojan Prof, Philipp Ströbel MD, Frank Becker MD, Christian Wülfing Prof, Peter Barth MD, Michael Stöckle Prof, Michael Staehler Prof, Christian Stief Prof, Axel Haferkamp Prof, Markus Hohenfellner Prof, Stephan Macher-Göppinger Prof, Bernd Wullich Prof, Joachim Noldus Prof, Walburgis Brenner MD, Frederik C. Roos Prof, Bernhard Walter MD, Wolfgang Otto Prof, Maximilian Burger Prof, Andres Jan Schrader Prof, Arndt Hartmann Prof, Yvonne Mondorf MD, Philipp Ivanyi MD, Marie Mikuteit MD, Sandra Steffens Prof, German Network Of Kidney Cancer
Description
Summary:The tyrosine-protein kinase c-Met plays a decisive role in numerous cellular processes, as a proto-oncogene that supports aggressive tumor behavior. It is still unknown whether c-Met could be relevant for prognosis of papillary RCC (pRCC). Specimen collection was a collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from 197 and 110 patients with type 1 and 2 pRCC, respectively. Expression of cMET was determined by immunohistochemistry. In total, cMET staining was evaluable in of 97 of 197 type 1 and 63 of 110 type 2 pRCC cases. Five-year overall survival revealed no significant difference in dependence of cMET positivity (cMET− vs. cMET+: pRCC type 1: 84.8% vs. 80.3%, respectively [p = 0.303, log-rank]; type 2: 71.4% vs. 64.4%, respectively [p = 0.239, log-rank]). Interestingly, the subgroup analyses showed a significant difference for cMET expression in T stage and metastases of the pRCC type 2 (p = 0.014, p = 0.022, chi-square). The cMET-positive type 2 collective developed more metastases than the cMET-negative cohort (pRCC type 2 M+: cMET−: 2 [4.3%] vs. cMET+: 12 [19%]). cMET expression did not qualify as a prognostic marker in pRCC for overall survival.
Item Description:Gesehen am 16.03.2022
Physical Description:Online Resource
ISSN:1532-8392
DOI:10.1016/j.humpath.2021.12.007

Similar Items